Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The user emphasizes hydration, androgen receptors, and a 7-day ejaculation recovery period for appearance enhancement. They suggest Minoxidil, finasteride, and RU58841 for hair loss, along with a diet rich in animal fats, specific exercises, and fasting.

The efficacy of taking dutasteride, a medication used to treat hair loss, every other day instead of daily. It was suggested that taking 0.5mg daily for 3 months and then switching to 3 times per week would be effective. Finasteride was also discussed as an alternative treatment option.

Ketoconazole shampoo may help with scalp health and inflammation but is not a substitute for DHT blockers like finasteride. It is generally considered a minor addition to hair loss treatment, with varying opinions on its effectiveness.

A user has been on oral Finasteride/Proscar for 15 years and started using topical Minoxidil, RU58841, and Dutasteride, along with microneedling, 2 years ago. They shared progress pictures and discussed their treatment routine.

Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.

Younger generations now view receding hairlines as baldness, increasing the use of treatments like minoxidil and finasteride. Social media and changing beauty standards have intensified focus on hairlines, altering perceptions of baldness.

Minoxidil is highly toxic to cats and dogs, even in small amounts. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

Male pattern baldness is linked to health risks and should be treated medically. Finasteride is effective and should be insurance-covered.

Finasteride can affect sperm quality, but fertility usually returns after stopping it, as shown by a user who conceived four months after discontinuation. Some users successfully conceive while on finasteride, though some prefer to pause its use to minimize risks.

User spent 23 years on Finasteride with side effects like weight gain and reduced libido. Switched to topical Finasteride, side effects reduced and waiting for results.

Finasteride may take over two years to show results and can cause side effects like sexual dysfunction and emotional changes. Alternatives such as dutasteride and minoxidil are discussed, with varying effectiveness and side effects.

DIM is suggested to help with estrogen metabolism for those on finasteride or dutasteride, potentially reversing side effects like fat gain and mood changes. Some users doubt its effectiveness, recommending lifestyle changes or consulting a doctor instead.

Finasteride and minoxidil can be obtained cheaply through Mark Cuban's Cost Plus Drugs and Costco's Kirkland brand, respectively, costing about $7.53/month combined. Amazon's RXPass and virtual visits at Dr. B. offer additional savings.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.

Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.

A 19-year-old was advised by their primary care provider to take biotin for hair loss instead of minoxidil or finasteride due to potential side effects and age concerns. The user is considering seeking a second opinion from a dermatologist.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

The conversation discusses various theories and suggestions for hair loss, with a focus on DHT as the primary cause. Treatments mentioned include Minoxidil, finasteride, and RU58841.